Residency · Residency · Obstetrics Gynecology
HPV Vaccination and Cervical Cancer Prevention
Human Papillomavirus Biology
Virology
HPV is a non-enveloped, double-stranded DNA virus of the Papillomaviridae family. Over 200 genotypes have been identified, with approximately 40 infecting the anogenital tract. High-risk oncogenic types include HPV 16, 18, 31, 33, 45, 52, and 58, among others. HPV 16 is the most oncogenic, causing approximately 60% of cervical cancers and the majority of HPV-related oropharyngeal cancers. HPV 18 causes approximately 15% of cervical cancers and is disproportionately associated with adenocarcinoma. Low-risk types 6 and 11 cause 90% of anogenital warts (condylomata acuminata) and recurrent respiratory papillomatosis.
Natural History
HPV is the most common sexually transmitted infection, with approximately 80% of sexually active individuals acquiring HPV by age 45. Most infections are transient and cleared by the immune system within 1 to 2 years. Persistent infection with high-risk HPV types is necessary for progression to high-grade dysplasia and cancer. This progression from HPV infection to cervical cancer typically takes 10 to 20 years. Risk factors for persistence include immunosuppression (particularly HIV), tobacco use, coinfection with multiple HPV types, and high viral load.
HPV and Cancer
Cervical cancer is virtually 100% attributable to HPV. Other HPV-attributable cancers include vaginal cancer (approximately 75%), vulvar cancer (approximately 70%), anal cancer (approximately 90%), oropharyngeal cancer (approximately 70%), and penile cancer (approximately 60%). In the United States, approximately 36,000 cancer cases annually are attributable to HPV.
<image>Diagram showing the natural history of HPV infection: initial HPV acquisition, transient infection cleared by immune response in 80-90% within 1-2 years, persistent infection in 10-20%, progression through CIN 1, CIN 2, CIN 3, and invasive cervical cancer over 10-20 years, with intervention points for screening and vaccination marked</image>
HPV Vaccines
Available Vaccines
Gardasil 9, the 9-valent HPV vaccine, is the only HPV vaccine currently available in the United States. It covers HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, providing protection against approximately 90% of cervical cancers and approximately 90% of genital warts. Previous vaccines, including the quadrivalent Gardasil (types 6, 11, 16, 18) and the bivalent Cervarix (types 16, 18), are no longer available in the United States.
Mechanism
The vaccine uses virus-like particles composed of the L1 major capsid protein. These particles are non-infectious because they contain no viral DNA, but they are highly immunogenic and induce neutralizing antibodies that prevent viral entry into basal epithelial cells. The vaccine is prophylactic only: it prevents new HPV infection but does not treat existing HPV infection or HPV-related disease.
Dosing Schedule
For individuals aged 9 to 14 (before the 15th birthday), a 2-dose schedule is used, with dose 1 on day 0 and dose 2 at 6 to 12 months, with a minimum interval of 5 months. For individuals aged 15 to 45, a 3-dose schedule is used, with dose 1 on day 0, dose 2 at 1 to 2 months, and dose 3 at 6 months. Immunocompromised individuals of any age receive the 3-dose schedule.
| Age Group | Schedule | Doses | Timing |
|---|---|---|---|
| 9-14 years | 2-dose | 2 | Day 0, 6-12 months (min 5 months apart) |
| 15-26 years | 3-dose | 3 | Day 0, 1-2 months, 6 months |
| 27-45 years | Shared decision-making | 3 | Day 0, 1-2 months, 6 months |
| Immunocompromised (any age) | 3-dose | 3 | Day 0, 1-2 months, 6 months |
Recommended Populations
Routine vaccination is recommended for all children at ages 11 to 12, though it can begin as early as age 9. Catch-up vaccination is available through age 26 for all individuals not previously vaccinated. For ages 27 to 45, shared clinical decision-making is appropriate rather than routine recommendation, since most individuals have already been exposed to HPV and the benefit is greatest for those not previously infected. Vaccination is gender-neutral, recommended for both males and females.
Efficacy Data
In HPV-naive individuals, the vaccine demonstrates 97 to 100% efficacy against HPV 16/18-related CIN 2/3, approximately 100% efficacy against CIN 3 or AIS, and approximately 99% efficacy against genital warts from HPV 6 and 11. Modest cross-protection exists against some non-vaccine HPV types. Real-world data from Australia, Scotland, and Scandinavian countries show near elimination of genital warts in vaccinated cohorts, an 87% reduction in CIN 3+ among vaccinated women in Scotland, and emerging data showing decreasing cervical cancer incidence in vaccinated cohorts.
Safety
Over 300 million doses have been administered worldwide with extensive safety monitoring through VAERS, VSD, CISA, and global registries. Common side effects include injection site pain (80%), mild fever, and headache. Syncope occurs more frequently in adolescents, and patients should be observed for 15 minutes after injection. No causal association has been established with autoimmune disease, infertility, chronic fatigue, or neurologic disorders. The vaccine is not routinely recommended during pregnancy, but no adverse outcomes have been reported, and the series should be completed after delivery. It can be administered with other routine vaccines.
<image>Bar graph comparing HPV vaccine efficacy data showing near 100% protection against HPV 16/18-related CIN 2/3, genital warts, and AIS in HPV-naive populations, alongside real-world population-level data from Australia and Scotland showing dramatic reductions in genital warts and high-grade cervical lesions after national vaccination programs</image>
Impact of National Vaccination Programs
Australia
Australia implemented a school-based program in 2007 for girls and expanded to boys in 2013, achieving approximately 80% coverage of the target population. The program has produced near elimination of genital warts in young women and men, a 77% reduction in high-grade cervical abnormalities in women screened at ages 20 to 24, and Australia is projected to be the first country to eliminate cervical cancer as a public health problem.
United Kingdom / Scotland
Strong evidence demonstrates reduced CIN 3+ incidence in vaccinated cohorts. The Falcaro study published in Lancet in 2021 found an 87% reduction in cervical cancer in women vaccinated at ages 12 to 13.
United States
Coverage rates remain lower than other high-income countries, with approximately 58% of adolescents up-to-date as of 2022. Racial and socioeconomic disparities in vaccination coverage persist. The Healthy People 2030 target is 80% coverage.
Counseling Strategies for Vaccine Hesitancy
Common Concerns and Responses
When parents express that their child is too young, the response should emphasize that the vaccine produces the strongest immune response at ages 9 to 12, requires only 2 doses instead of 3 when given at that age, and initiates cancer prevention before exposure. Regarding concerns about promoting sexual activity, multiple studies demonstrate no association between HPV vaccination and earlier sexual debut, more sexual partners, or increased STI rates. For safety concerns, the track record of over 300 million doses worldwide with extensive safety monitoring and no confirmed serious safety signals should be emphasized. When asked why boys need the vaccine, the explanation should include that HPV causes cancers in men as well, including oropharyngeal, anal, and penile cancers, and that male vaccination contributes to herd immunity.
Effective Counseling Approaches
A strong provider recommendation is the single most influential factor in vaccine acceptance. The presumptive approach ("Your child is due for the HPV vaccine today") is more effective than the participatory approach ("Would you like to discuss the HPV vaccine?"). Framing the vaccine as cancer prevention rather than STI prevention is important. Same-day vaccination should be used to avoid missed opportunities. Specific concerns should be addressed without dismissing them.
HPV Vaccination and Screening Integration
Vaccinated women still require cervical cancer screening because the vaccine does not cover all oncogenic HPV types. They follow the same screening guidelines as unvaccinated women. As vaccinated cohorts age, the positive predictive value of screening tests will decrease due to the lower prevalence of HPV-related disease, and screening strategies may need to be adapted in the future for highly vaccinated populations.
Global Cervical Cancer Elimination Strategy (WHO)
WHO 2020 Global Strategy (90-70-90 Targets by 2030)
The WHO targets call for 90% of girls fully vaccinated with the HPV vaccine by age 15, 70% of women screened with a high-performance test by age 35 and again by age 45, and 90% of women with precancer or cancer receiving appropriate treatment. The goal is to reduce cervical cancer incidence to below 4 per 100,000 women globally.
Barriers
Barriers include vaccine access and cost in low- and middle-income countries. The WHO now recommends a single dose as an acceptable alternative to multi-dose schedules (as of 2022), which dramatically improves feasibility. Other barriers include cold chain logistics, screening infrastructure in resource-limited settings, and cultural and political barriers to vaccination programs.
<image>World map illustrating global HPV vaccination coverage rates by country, highlighting high-coverage countries like Australia, UK, and Scandinavian nations in one color, moderate-coverage countries like the US in another, and low-coverage regions in sub-Saharan Africa and South Asia, with WHO 90-70-90 targets annotated</image>
Clinical Pearls
The strongest predictor of HPV vaccine uptake is a clear, strong provider recommendation. The presumptive approach should be used.
HPV vaccination at ages 9 to 12 requires only 2 doses and produces a superior immune response compared with vaccination at older ages.
Vaccination does not replace cervical cancer screening. Vaccinated women follow the same screening schedule as unvaccinated women.
The 9-valent vaccine covers HPV types responsible for approximately 90% of cervical cancers.
The WHO now recommends single-dose HPV vaccination as an acceptable alternative to multi-dose schedules, greatly increasing global feasibility.
Real-world data from Australia and the UK demonstrate that HPV vaccination programs are reducing cervical cancer incidence, not just precancerous lesions.
Catch-up vaccination through age 26 is routine. Shared clinical decision-making extends to age 45 for select patients.
References
- ACOG Committee Opinion No. 809: Human Papillomavirus Vaccination (2020)
- CDC Advisory Committee on Immunization Practices (ACIP): HPV Vaccine Recommendations (Updated 2023)
- Falcaro M et al. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence. Lancet. 2021;398:2084-2092
- Lei J et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med. 2020;383:1340-1348
- WHO Guideline: One-dose Human Papillomavirus Vaccination Schedule (2022)
- WHO Global Strategy to Accelerate the Elimination of Cervical Cancer (2020)
- Markowitz LE et al. Human papillomavirus vaccination: recommendations of the ACIP. MMWR. 2014;63(RR05):1-30
